Hyogo, Japan

Jun-ichi Mizoguchi


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2002

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jun-ichi Mizoguchi: Innovator in Pharmaceutical Composition

Introduction

Jun-ichi Mizoguchi is a notable inventor based in Hyogo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of Helicobacter pylori infections. His innovative work has led to the development of a unique pharmaceutical composition that showcases his expertise and dedication to improving healthcare.

Latest Patents

Mizoguchi holds a patent for a cyclohexane carbocyclic ester derivative and cyclodextrin complex, which is specifically designed for the treatment of Helicobacter pylori infections. The patent details a pharmaceutical composition that effectively eradicates or exterminates the bacteria, utilizing compounds such as [4-[4-(4-methylbenzyloxycarbonyl)phenyl][phenyl trans-4-guanidinomethylcyclohexanecarboxylate or an acid addition salt thereof. This invention represents a significant advancement in the fight against this common infection.

Career Highlights

Mizoguchi is associated with Teikoku Chemical Industries Co., Ltd., where he has been instrumental in developing innovative pharmaceutical solutions. His work has not only contributed to the company's reputation but has also had a positive impact on public health.

Collaborations

Mizoguchi has collaborated with esteemed colleagues, including Osamu Kamoda and Toshiharu Yanagi. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Jun-ichi Mizoguchi's contributions to pharmaceutical innovation, particularly in the treatment of Helicobacter pylori infections, highlight his role as a leading inventor in the field. His work continues to inspire advancements in healthcare and demonstrates the importance of innovation in addressing medical challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…